Pfizer Basic Shares Outstanding 2012-2026 | PFE
Pfizer annual/quarterly basic shares outstanding history and growth rate from 2012 to 2026. Basic shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares.
- Pfizer basic shares outstanding for the quarter ending March 31, 2026 were $5.691B, a 0.28% increase year-over-year.
- Pfizer basic shares outstanding for the twelve months ending March 31, 2026 were $22.747B, a 0.33% increase year-over-year.
- Pfizer annual basic shares outstanding for 2025 were $5.683B, a 0.34% increase from 2024.
- Pfizer annual basic shares outstanding for 2024 were $5.664B, a 0.37% increase from 2023.
- Pfizer annual basic shares outstanding for 2023 were $5.643B, a 0.62% increase from 2022.
|
Pfizer Annual Basic Shares Outstanding (Millions of US $) |
|
|---|---|
| 2025 | $5,683 |
| 2024 | $5,664 |
| 2023 | $5,643 |
| 2022 | $5,608 |
| 2021 | $5,601 |
| 2020 | $5,555 |
| 2019 | $5,569 |
| 2018 | $5,872 |
| 2017 | $5,970 |
| 2016 | $6,089 |
| 2015 | $6,176 |
| 2014 | $6,346 |
| 2013 | $6,813 |
| 2012 | $7,442 |
| 2011 | $7,817 |
|
Pfizer Quarterly Basic Shares Outstanding (Millions of US $) |
|
|---|---|
| 2026-03-31 | $5,691 |
| 2025-12-31 | $5,686 |
| 2025-09-30 | $5,685 |
| 2025-06-30 | $5,685 |
| 2025-03-31 | $5,675 |
| 2024-12-31 | $5,664 |
| 2024-09-30 | $5,667 |
| 2024-06-30 | $5,666 |
| 2024-03-31 | $5,657 |
| 2023-12-31 | $5,643 |
| 2023-09-30 | $5,646 |
| 2023-06-30 | $5,646 |
| 2023-03-31 | $5,634 |
| 2022-12-31 | $5,608 |
| 2022-09-30 | $5,607 |
| 2022-06-30 | $5,593 |
| 2022-03-31 | $5,617 |
| 2021-12-31 | $5,601 |
| 2021-09-30 | $5,609 |
| 2021-06-30 | $5,598 |
| 2021-03-31 | $5,584 |
| 2020-12-31 | $5,555 |
| 2020-09-30 | $5,557 |
| 2020-06-30 | $5,554 |
| 2020-03-31 | $5,545 |
| 2019-12-31 | $5,569 |
| 2019-09-30 | $5,545 |
| 2019-06-30 | $5,562 |
| 2019-03-31 | $5,635 |
| 2018-12-31 | $5,872 |
| 2018-09-30 | $5,875 |
| 2018-06-30 | $5,866 |
| 2018-03-31 | $5,957 |
| 2017-12-31 | $5,970 |
| 2017-09-30 | $5,951 |
| 2017-06-30 | $5,958 |
| 2017-03-31 | $6,006 |
| 2016-12-31 | $6,089 |
| 2016-09-30 | $6,066 |
| 2016-06-30 | $6,068 |
| 2016-03-31 | $6,150 |
| 2015-12-31 | $6,176 |
| 2015-09-30 | $6,168 |
| 2015-06-30 | $6,159 |
| 2015-03-31 | $6,203 |
| 2014-12-31 | $6,346 |
| 2014-09-30 | $6,330 |
| 2014-06-30 | $6,368 |
| 2014-03-31 | $6,389 |
| 2013-12-31 | $6,813 |
| 2013-09-30 | $6,581 |
| 2013-06-30 | $7,042 |
| 2013-03-31 | $7,187 |
| 2012-12-31 | $7,442 |
| 2012-09-30 | $7,436 |
| 2012-06-30 | $7,476 |
| 2012-03-31 | $7,537 |
| 2011-12-31 | $7,817 |
| 2011-09-30 | $7,770 |
| 2011-06-30 | $7,875 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |